Nature Biotechnology, Published online: 04 August 2025; doi:10.1038/s41587-025-02792-9
Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Seaport Therapeutics is modifying central nervous system drugs for delivery through the lymphatic system, bypassing first-pass liver metabolism.
